Pfizer stock jumps, Moderna, Merck fall

Pfizer started the vaccine wars on Friday after it was revealed that its oral pill against COVID-19 was 89% effective to prevent hospitalization.

Stocks are on track for the largest percentage increase since March 2009, as observed by the Dow Jones Market Group. Today alone, around $ 30 billion in market value has been created for the pharmaceutical manufacturer based on the promise of treatment.

Neil Cavuto, CEO of Pfizer, Albert Bourla FOX Business, is a game changer for COVID-19 patients and should get approval quickly.

“I can’t tell how long the FDA will take, but I can tell you we’ll be filing that before the end of the month, probably before Thanksgiving. Then it’s up to them to give approval. I suspect they.” will do it. ” So sometime in December we will have a few million pills this year, “he said.

The news from Pfizer comes after the Biden government ordered companies with over 100 employees to put in place vaccine mandates, due to begin January 4, 2022.

BIDEN-ADMIN HAS A VACCINATION MANDATE FOR COMPANIES WITH LESS THAN 100 EMPLOYEES

As Pfizer advances, other vaccine providers are losing ground.

Rival Merck, which has competing COVID-19 treatment, is well on its way to seeing the largest one-day decline since January 2005.

CLICK HERE TO READ MORE ABOUT FOX BUSINESS

Moderna lowered its forecast for the full fiscal year 2021 earlier this week COVID-19 Vaccine deliveries. The stock remained under pressure.

“Key variables affecting production include longer delivery times for international shipments and exports that may postpone deliveries to early 2022, temporary effects from expanding filling / processing capacity and ramping up product release to the market”, said Moderna in his Third–Quarterly results publication.

Regeneron, which makes a COVID-19 antibody cocktail, also saw stocks decline.